statistiche ricercatore

Continente	#
AS - Asia	462
NA - Nord America	392
EU - Europa	232
SA - Sud America	71
AF - Africa	18
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.176

Nazione	#
US - Stati Uniti d'America	381
SG - Singapore	208
CN - Cina	100
BR - Brasile	58
IT - Italia	47
VN - Vietnam	37
FR - Francia	34
DE - Germania	33
IN - India	31
GB - Regno Unito	24
FI - Finlandia	20
IE - Irlanda	18
JP - Giappone	15
ID - Indonesia	13
HK - Hong Kong	12
KR - Corea	12
SE - Svezia	10
AR - Argentina	9
NL - Olanda	9
IQ - Iraq	8
RU - Federazione Russa	8
AT - Austria	7
BD - Bangladesh	7
ES - Italia	6
ZA - Sudafrica	6
CA - Canada	5
MA - Marocco	4
SA - Arabia Saudita	4
PL - Polonia	3
AW - Aruba	2
CH - Svizzera	2
CZ - Repubblica Ceca	2
DZ - Algeria	2
HU - Ungheria	2
IL - Israele	2
LT - Lituania	2
MX - Messico	2
OM - Oman	2
PK - Pakistan	2
UZ - Uzbekistan	2
VE - Venezuela	2
AO - Angola	1
BE - Belgio	1
BG - Bulgaria	1
CI - Costa d'Avorio	1
EC - Ecuador	1
ET - Etiopia	1
GA - Gabon	1
GE - Georgia	1
HN - Honduras	1
IR - Iran	1
JO - Giordania	1
KE - Kenya	1
KZ - Kazakistan	1
LK - Sri Lanka	1
MY - Malesia	1
PY - Paraguay	1
RO - Romania	1
SI - Slovenia	1
SN - Senegal	1
TR - Turchia	1
TT - Trinidad e Tobago	1
UA - Ucraina	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.176

Nome	#
Recent progress in the use of pharmacotherapy for endometrial cancer	117
PARP Inhibitors Resistance: Mechanisms and Perspectives	114
Advanced and recurrent endometrial cancer: State of the art and future perspectives	110
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?	105
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study	99
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	96
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives	89
Pembrolizumab for advanced cervical cancer: safety and efficacy	89
Evolution of Clinical Trials in Ovarian Cancer Management over the Past 20 Years: Never Settle Down, Always Go beyond	83
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	77
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors	74
Genome tumor profiling in endometrial cancer and clinical relevance in endometrial cancer management: A retrospective single-center experience	72
Management of stage III and IVa uterine cancer	69
Totale	1.194

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	1	0	0	0	0	0	0	0	0	0	0	1	0
2021/2022	25	0	0	0	5	0	0	1	7	2	1	2	7
2022/2023	84	6	9	2	9	2	8	4	3	6	9	19	7
2023/2024	157	4	25	17	16	4	21	19	3	5	5	18	20
2024/2025	319	8	4	31	6	20	20	14	6	30	54	78	48
2025/2026	607	82	22	40	79	114	46	117	37	43	27	0	0
Totale													1.194

IRIS UniCatt